Phases, a new telehealth platform founded by Los Angeles-based husband-and-wife team Lana and Joseph Elie-Meyers, is launching with nine peptide-based treatment options designed around women’s health needs, from postpartum care to perimenopause and menopause.
Chief executive Lana Elie-Meyers said her own postpartum health experience, including anxiety, eczema and brain fog, led her to explore peptides and identify a gap in care tailored to women. She previously founded floral marketplace Floom, which was acquired by BloomNation in 2025. Chief operating officer Joseph Elie-Meyers, a former civil rights litigator, has drawn on his legal experience to navigate the regulatory landscape.
The launch range starts at $145 a month and covers metabolism, energy, recovery and sexual wellness. Options include tirzepatide combined with glycine or B12, administered by weekly injection and priced from $275 a month, as well as sermorelin, MIC with B12, NAD+, glutathione, PT-141 and oxytocin. Treatments include injectables and nasal sprays.
To access care, patients complete an online medical intake for physician review. If a treatment is prescribed, it is fulfilled through partner 503(a) compounding pharmacies. Phases also offers medical guidance and direct communication with physicians.
Joseph Elie-Meyers said the FDA had shifted toward channeling some increasingly popular peptides through prescription pathways. The launch comes as U.S. Health Secretary Robert F. Kennedy Jr. has moved to ease restrictions on compounding six peptides, including BPC-157 and TB-500, which have gained attention through influencers despite lacking FDA approval. The other peptides named are epitalon, KPV, MOTS-c and Semax.
Sources: WWD.